Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024 Three abstracts accepted for poster presentations on ALG-000184 and ALG-055009

Saved in:
Bibliographic Details
Published inNASDAQ OMX's News Release Distribution Channel
Format Newsletter
LanguageEnglish
Published New York NASDAQ OMX Corporate Solutions, Inc 15.10.2024
Subjects
Clinical outcomes
Clinical trials
Gastroenterology
Hepatitis B
Hepatology
Liver
Metabolism
Regulatory approval
Thyroid gland
Online AccessGet full text

Cover

More Information
Description not available.